Genenta Strengthens Agreement with AGC Biologics to Boost Cell Therapy Manufacturing

Core Insights - Genenta Science has strengthened its partnership with AGC Biologics by amending their Development and Master Services Agreement, introducing an exclusive GMP suite for the manufacturing of Genenta's cell therapy product [1] - The company is advancing its clinical trials, including a Phase 1/2a trial for metastatic Renal Cell Carcinoma (mRCC) and continuing its study on Glioblastoma Multiforme (GBM), with plans to manufacture 27 autologous drug products in 2025 [2][4] - Genenta's CEO emphasized the commitment to patients and the potential of their product, Temferon, to enhance cancer treatment through reprogramming the tumor microenvironment [3] Company Developments - The exclusive GMP suite at AGC Biologics will ensure compliance with cGMP standards, enhancing production capabilities and efficiency for Genenta's cell therapy products [1] - Genenta's first product candidate, Temferon™, aims to express immune-therapeutic payloads within the tumor microenvironment, potentially breaking immune tolerance and enhancing T-cell responses [4] - The company has completed a Phase 1 trial for newly diagnosed GBM patients and initiated a Phase 1/2a study for mRCC, which may include combinations with immune checkpoint inhibitors [4] Upcoming Engagements - Genenta will participate in the Biotech Showcase 2025 from January 13–15, 2025, in San Francisco to present its technology for treating solid tumors [3] - The CEO will also speak at the "Italy on the Move" event on January 15, 2025, aimed at promoting Italy's life sciences sector and attracting international investments [3]